Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.645
−$0.0049 · -0.75%
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Previous close
$0.645
−$0.0049 · -0.75%
Pre-market
$0.633
−$0.012 · -1.86%
Oct 8, 8:26 AM ET
Regular session · ET · Market data may be delayed.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Day range
Current $0.645
52-week range
Current $0.645
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
51
Fair Value
Sentiment
69
Bullish
Risk
45
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Day range
Current $0.645
52-week range
Current $0.645
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 146.07M USD | 145.24M USD | 146.03M USD | 157.07M USD | 209.82M USD |
| Cost of goods sold | 5.95M USD | 6.01M USD | 4.94M USD | 5.21M USD | 3.4M USD |
| Gross profit | 140.12M USD | 139.23M USD | 141.09M USD | 151.86M USD | 206.42M USD |
| Research and development | 125.62M USD | 143.23M USD | 138.75M USD | 148.66M USD | 160.84M USD |
| Selling, general, and administrative | 105.21M USD | 115.44M USD | 131.88M USD | 145.4M USD | 143.85M USD |
| Operating expenses | 230.83M USD | 258.67M USD | 270.63M USD | 294.06M USD | 304.69M USD |
| Interest income | 2.77M USD | 7.4M USD | 10.94M USD | 2.36M USD | 582K USD |
| Interest expense | 45.85M USD | 37.42M USD | 23.82M USD | 25M USD | 26.05M USD |
| Depreciation and amortization | 296K USD | 340K USD | 530K USD | 621K USD | 789K USD |
| Operating income | −90.71M USD | −119.44M USD | −129.54M USD | −142.2M USD | −98.27M USD |
| Net income | −196.04M USD | −76.42M USD | −143.1M USD | −165.29M USD | −124.09M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.4M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF541.95K0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 ETFIWM322.94K0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Russell 2000 ETFVTWO234.39K0.00%18B USD0.06%$112.21-1.26%
Fidelity Enhanced Small Cap ETFFESM118.05K—6.41B USD0.28%$45.22-1.14%
iShares Micro-Cap ETFIWC41.22K0.00%1.33B USD0.60%$183.36-1.09%
Invesco NASDAQ Future Gen 200 ETFQQQS37.61K0.16%22.96M USD0.20%$42.026-1.20%
Vanguard Russell 2000 Value ETFVTWV32.35K0.00%1.4B USD0.06%$184.96-1.15%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
